FDMT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

662.50K

+13150%

-0.697

+10.67%

662.50K

+21983.33%

-0.944

+19.51%

1.16M

+116150%

-0.882

-2.01%

Estimates Revision

The market is revising No Change the revenue expectations for 4D Molecular Therapeutics, Inc. (FDMT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -23.64%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-23.64%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast FDMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FDMT is 29.40 USD with a low forecast of 17.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

17.00

Averages

29.40

High

38.00

Current: 0.000

Low

17.00

Averages

29.40

High

38.00

RBC Capital

Lisa Walter

Outperform

maintain

$26 -> $32

2025-11-11

Reason

RBC Capital

Lisa Walter

Price Target

$26 -> $32

2025-11-11

maintain

Outperform

Reason

RBC Capital analyst Lisa Walter raised the firm's price target on 4D Molecular to $32 from $26 and keeps an Outperform rating on the shares after its Q3 results. The company's current cash position of $372M plus additional funds from the recent APAC deal with Otsuka and capital raise should extend the runway by 6 months into the second half of FY28 and fund both wAMD and DME pivotals, the analyst tells investors in a research note, adding that the recent funding "adds some cushion to the runway".

Barclays

Gena Wang

Overweight

downgrade

$38 -> $33

2025-11-11

Reason

Barclays

Gena Wang

Price Target

$38 -> $33

2025-11-11

downgrade

Overweight

Reason

Barclays analyst Gena Wang lowered the firm's price target on 4D Molecular to $33 from $38 and keeps an Overweight rating on the shares. The firm views the company's Q3 update as "largely incremental." The Otsuka deal and equity offering extend 4D's cash runway to the second half of 2028, the analyst tells investors in a research note.

Morgan Stanley

Judah Frommer

Underweight -> Equal Weight

upgrade

2025-11-06

Reason

Morgan Stanley

Judah Frommer

Price Target

2025-11-06

upgrade

Underweight -> Equal Weight

Reason

Morgan Stanley analyst Judah Frommer upgraded 4D Molecular to Equal Weight from Underweight. The firm is also raising its price target view on the stock to a range of $7-$16 from the prior range of $3-$7. Morgan Stanley notes that class safety concerns among physicians and commercial dynamics have driven its view of retinal disease gene therapy to date. The firm notes however that its new rating is based on the continued positive data for 4D-150, recent biopharma interest, and growing enthusiasm for 4D-150 among key opinion leaders, the analyst tells investors in a research note.

Leerink

Outperform

NULL

downgrade

$17 -> $16

2025-08-11

Reason

Leerink

Price Target

$17 -> $16

2025-08-11

downgrade

Outperform

NULL

Reason

Leerink lowered the firm's price target on 4D Molecular to $16 from $17 and keeps an Outperform rating on the shares after the company announced Q2 results and completion of enrollment in the lower dose cohorts of the Phase 1 trial of 4D-710 in cystic fibrosis. The firm's revised target reflects updated R&D expense estimates for ongoing pivotal trials, the analyst noted.

Barclays

Gena Wang

Overweight

downgrade

$45 -> $38

2025-05-09

Reason

Barclays

Gena Wang

Price Target

$45 -> $38

2025-05-09

downgrade

Overweight

Reason

Barclays analyst Gena Wang lowered the firm's price target on 4D Molecular to $38 from $45 and keeps an Overweight rating on the shares. The firm updated the company's model post the Q1 report.

B of A Securities

Tazeen Ahmad

Strong Buy

Maintains

$42 → $40

2025-03-10

Reason

B of A Securities

Tazeen Ahmad

Price Target

$42 → $40

2025-03-10

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for 4D Molecular Therapeutics Inc (FDMT.O) is -1.26, compared to its 5-year average forward P/E of -5.83. For a more detailed relative valuation and DCF analysis to assess 4D Molecular Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.83

Current PE

-1.26

Overvalued PE

-2.20

Undervalued PE

-9.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.26

Current EV/EBITDA

1.44

Overvalued EV/EBITDA

0.85

Undervalued EV/EBITDA

-7.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

117.87

Current PS

56.68

Overvalued PS

207.76

Undervalued PS

27.99

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

FDMT News & Events

Events Timeline

No data

News

2.0

2025-12-19Benzinga

Major Stocks Including BlackBerry, FedEx, and Nike Decline in Friday's Pre-Market Trading

9.0

2025-12-17SeekingAlpha

4D Molecular Shares Decline Following Initial Trial Results for Cystic Fibrosis Treatment

9.0

2025-12-17Globenewswire

4D Molecular Therapeutics Reports Positive Interim Data for 4D-710 in Cystic Fibrosis Trial

People Also Watch

Frequently Asked Questions

What is 4D Molecular Therapeutics Inc (FDMT) stock price today?

The current price of FDMT is 7.3 USD — it has decreased -6.05 % in the last trading day.

What is 4D Molecular Therapeutics Inc (FDMT)'s business?

4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.

What is the price predicton of FDMT Stock?

What is 4D Molecular Therapeutics Inc (FDMT)'s revenue for the last quarter?

4D Molecular Therapeutics Inc revenue for the last quarter amounts to 14.00K USD, decreased -50.00 % YoY.

What is 4D Molecular Therapeutics Inc (FDMT)'s earnings per share (EPS) for the last quarter?

4D Molecular Therapeutics Inc. EPS for the last quarter amounts to -0.86 USD, increased 30.30 % YoY.

What changes have occurred in the market's expectations for 4D Molecular Therapeutics Inc (FDMT)'s fundamentals?

How many employees does 4D Molecular Therapeutics Inc (FDMT). have?

4D Molecular Therapeutics Inc (FDMT) has 227 emplpoyees as of January 09 2026.

What is 4D Molecular Therapeutics Inc (FDMT) market cap?

Today FDMT has the market capitalization of 1.08B USD.